



For Immediate Release

February 11, 2025

## Acuitas Therapeutics Named One of BC's Top Employers

**Vancouver, B.C.** – Today, Acuitas Therapeutics, Inc. was named one of [BC's Top Employers of 2025](#). The Vancouver-based, privately held biotechnology firm is the global leader in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles.

“We are honoured to – once again – be named as one of BC's Top Employers,” said Chief Operating Officer Abi Coman-Walker. She added: “Since the first day of Acuitas, there has been a deep commitment to a company culture where everyone feels respected, heard and valued. Our team is made up of some of the world's best scientists and business professionals, and we are dedicated to ongoing innovation in scientific research to help people around the world live healthier lives. Our scientific innovation attracts exceptional talent, and the Acuitas culture of innovation, collaboration and belonging retains them. It is a great combination.”

### About Acuitas Therapeutics

Vancouver-based Acuitas Therapeutics ([www.acuitastx.com](http://www.acuitastx.com)) is the global leader in lipid nanoparticle (LNP) technology and partners with pharmaceutical and biotechnology companies, as well as non-governmental organizations and academic institutes, to advance nucleic acid therapeutics into clinical development and commercialization. Acuitas' LNP technology is clinically validated, enabling Alnylam Pharmaceuticals' ONPATRO® for the treatment of people with a rare genetic and otherwise fatal disorder known as transthyretin amyloidosis and the Pfizer-BioNTech COVID-19 vaccine, COMIRNATY®, which has protected billions of people in over 180 countries. Acuitas has also helped to enable the first human proof-of-concept for genome base editing to treat a serious genetic disease. The company is currently focused on further innovations to its LNP carriers to advance the development of novel gene therapies, such as epigenetic medicines, to modulate gene expression without genetic editing to treat a range of diseases, including cancer. In addition, Acuitas works on identification of potent new lipids to enable partners to develop improved and new vaccines to prevent a range of infectious diseases (i.e., malaria, HIV/AIDS and tuberculosis), multivalent vaccines, and novel therapeutic vaccines against cancer, including personalized cancer vaccines.

-END-